Lactate

NutraPedia - Evidence-Based Supplement Research

Back to Table of Contents
Health Goals: energy muscle heart

Research Overview

Across the abstracts, lactate research is most heavily concentrated in cancer metabolism and the tumor microenvironment (TME), anchored by the Warburg effect (aerobic glycolysis with high lactate output). Major themes include: (i) mechanistic interpretations of why tumors produce lactate despite functional mitochondria (with ongoing debate, including models such as “mitochondrial saturation/overload” rather than mitochondrial suppression); (ii) lactate as a mediator of TME acidification and metabolic crosstalk via lactate shuttling and monocarboxylate transporters (MCTs); (iii) lactate’s immunoregulatory roles affecting innate and adaptive immunity; and (iv) lactate-driven signaling and epigenetic regulation, particularly histone lactylation, as a means by which lactate can influence gene expression and cell fate. Therapeutic work most often targets lactate production and transport (e.g., LDH and MCT inhibition) and positions these interventions as potentially synergistic with immunotherapy. Beyond oncology, lactate is also being studied in inflammation and tissue remodeling/fibrosis, exemplified by hepatic stellate cell activation and liver fibrosis models linked to glycolytic enzymes (e.g., HK2) and histone lactylation.

The strongest convergent evidence supports lactate as more than a glycolytic waste product: it functions as a metabolite that shapes cellular behavior through (a) microenvironmental effects (notably extracellular acidification in tumors), (b) intercellular metabolic coupling (lactate shuttles and transporter-dependent uptake/export), (c) immune modulation (with consistent emphasis on impaired T-cell function and macrophage reprogramming in lactate-rich TMEs), and (d) gene-regulatory mechanisms including histone lactylation. Multiple abstracts also support lactate as a therapeutic vulnerability: inhibiting lactate generation (e.g., via LDH or upstream glycolytic control) or transport (MCTs) can suppress tumor-promoting phenotypes and may enhance responses to immunotherapy. Mechanistic evidence is also emerging that lactate availability can alter stress resistance pathways, including resistance to ferroptosis via MCT1-dependent uptake and downstream lipid metabolic remodeling in liver cancer models.

Key areas needing further research include: resolving the primary functional rationale of the Warburg effect across tumor types (including quantitative tests of “mitochondrial overload” versus alternative explanations); establishing causal, context-specific links between lactate levels, lactate flux (production vs uptake), and immune dysfunction in vivo; and clarifying the scope, regulation, and functional specificity of lactylation relative to competing acylations (e.g., acetylation), including how these marks integrate with chromatin state and transcriptional programs. Translational gaps remain for lactate-targeted therapies, including biomarker-guided patient stratification, on-target/off-tumor effects in normal tissues that use lactate physiologically, and optimal combination strategies (especially with immunotherapy and ferroptosis-inducing approaches). Finally, broader disease coverage and standardized measurement of lactate dynamics (spatial/temporal gradients, compartmental pH, transporter expression, and flux) are needed to move from associative observations to predictive, mechanism-based interventions.

1. What conditions has Lactate been studied for?

  • Cancer biology and cancer treatment targeting metabolism: Lactate is central to the Warburg effect (aerobic glycolysis) and has been studied across multiple tumor contexts and mechanisms (tumor growth, metastasis, angiogenesis, immune evasion, drug resistance, and as a therapeutic target via LDH/MCT inhibition).

  • Tumor immunology / immunotherapy response: Multiple abstracts describe lactate-driven immunosuppression in the tumor microenvironment (TME), including impaired T-cell function and macrophage reprogramming, and propose lactate metabolism targeting to enhance immunotherapy.

  • Liver cancer (hepatocellular carcinoma, HCC): Lactate uptake via MCT1 is described as promoting resistance to ferroptosis in HCC, with therapeutic implications for ferroptosis-based treatments.

  • Acute myeloid leukemia (AML): Lactate accumulation is linked to histone lactylation and increased PD-L1 transcription (immunosuppressive signaling), suggesting relevance to checkpoint blockade strategies.

  • Brain tumors / glioblastoma (GBM): LDHA and the Warburg effect are discussed as relevant to primary brain tumors, with LDHA proposed as a target (noting lack of suitable clinical inhibitors).

  • Liver fibrosis:

    • Hepatic stellate cell (HSC) activation and fibrosis: Lactate-driven histone lactylation (dependent on HK2) is described as determining HSC fate and promoting fibrosis; HK2 deletion inhibits fibrosis in vivo.

    • Overtraining-associated hepatic fibrosis: Excess skeletal muscle lactate is linked to lactylation-driven extracellular vesicle (“lactate bodies”) signaling that induces hepatocyte apoptosis and subsequent HSC activation, promoting fibrosis.

  • Inflammation and immune-related diseases (broad): Reviews cite lactylation and lactate signaling as involved in inflammation, infection, cardiovascular diseases, and autoimmunity (as areas of relevance), though details in these abstracts are higher-level.

  • Neural excitation: Lactylation is noted as being involved in neural excitation (mentioned in a review abstract).

2. Does it work in treating those conditions? Summarize the evidence.

  • As a direct “treatment” (supplement/administration): not supported in these abstracts. The abstracts largely frame lactate as a signaling metabolite that can promote pathology (especially in cancer and fibrosis) rather than as a therapeutic agent to administer.

  • Cancer: evidence supports targeting lactate production/transport rather than adding lactate.

    • Multiple reviews state that focusing on lactate production and transport (via lactate dehydrogenase, LDH, and monocarboxylate transporters, MCT) “has shown promise” and may synergize with immunotherapy by reducing tumor-supportive lactate signaling and immunosuppression.

    • However, one brain tumor/GBM-focused review explicitly notes that there are currently no suitable LDHA inhibitors available for tumor therapies in the clinic, highlighting a translational gap.

    • Several abstracts emphasize that while the Warburg effect is a hallmark and a target, achieving therapeutic efficacy is challenging (pharmacologic strategies face obstacles).

  • HCC ferroptosis sensitization: mechanistic in vitro/in vivo evidence supports blocking lactate uptake/signaling.

    • One study reports that lactate-rich liver cancer cells resist ferroptosis induced by RSL3 and erastin, and that MCT1-mediated lactate uptake increases ATP, deactivates AMPK, and upregulates SREBP1/SCD1 to generate anti-ferroptosis monounsaturated fatty acids.

    • It further reports that HCAR1/MCT1 inhibition promotes ferroptosis (via AMPK activation and SCD1 downregulation), with in vitro and in vivo evidence, positioning lactate uptake as a therapeutic target in ferroptosis-based tumor treatment.

  • Liver fibrosis (HSC activation): evidence supports reducing lactate production or HK2 activity; exogenous lactate can worsen/restore activation.

    • One mechanistic study reports that HK2 induction is required for lactate-driven histone lactylation and gene expression in activated HSCs; inhibiting lactate production or deleting Hk2 diminishes HSC activation.

    • Importantly, exogenous lactate (but not acetate) rescues the activation phenotype, supporting a causal role for lactate in promoting HSC activation.

    • It also reports HSC-specific or systemic HK2 deletion inhibits HSC activation and liver fibrosis in vivo, suggesting HK2 as a therapeutic target.

  • Overtraining-associated fibrosis: evidence supports blocking lactylation-mediated signaling rather than using lactate.

    • A study reports that overtraining causes excess lactate accumulation leading to SORBS3 lactylation, extracellular vesicle (“lactate bodies”) formation, hepatocyte apoptosis, and HSC activation; inhibiting SORBS3 lactylation or FBXO2 alleviates fibrosis.

  • AML immunotherapy context: evidence suggests lactate promotes immune evasion (PD-L1) rather than treating AML.

    • An AML abstract reports STAT5-driven glycolysis increases lactate, which promotes E3BP nuclear translocation and histone lactylation, inducing PD-L1 transcription—a mechanism consistent with lactate contributing to immunosuppression rather than therapeutic benefit.

Overall, across these abstracts, the therapeutic direction is predominantly anti-lactate signaling/metabolism (LDH/MCT/HK2/HCAR1 pathways) rather than lactate administration.

3. What health benefits does it have?

  • Physiological roles (general): Reviews describe lactate as more than a “waste product,” acting as:

    • A fuel/energy substrate and part of intercellular metabolic coordination (the “lactate shuttle hypothesis”).

    • A signaling molecule coordinating signaling among cells, organs, and tissues.

    • A regulator of gene expression via histone modification (lactylation), influencing cellular differentiation and fate decisions.

  • Immune regulation (context-dependent): One review highlights lactate’s diverse roles in regulating adaptive and innate immune responses during homeostasis and disease—indicating lactate can be part of normal immune signaling, though the abstracts emphasize harmful roles in cancer settings.

Important limitation: the provided abstracts do not present clinical evidence that increasing lactate (e.g., supplementation) improves health outcomes; “benefits” here refer mainly to recognized physiological functions.

4. Does it have any downsides or side effects?

  • Cancer-promoting microenvironment effects:

    • High lactate production is tied to the Warburg effect and is described as shaping the TME to support tumor progression.

    • One review notes extracellular acidification in tumors (pH ~6.0–6.5) associated with high lactate, which favors metastasis, angiogenesis, and immunosuppression and correlates with worse prognosis.

    • Multiple abstracts describe lactate as contributing to immune evasion (e.g., impaired T-cell function, macrophage reprogramming) and treatment resistance.

  • Epigenetic reprogramming that can worsen disease:

    • Histone lactylation is repeatedly implicated in pathological gene expression programs (e.g., HSC activation in fibrosis; PD-L1 induction in AML via lactylation-linked mechanisms).

  • Ferroptosis resistance in liver cancer: Lactate uptake via MCT1 is reported to promote metabolic changes that increase resistance to ferroptotic cell death, potentially undermining ferroptosis-based therapies.

  • Overtraining-associated liver injury/fibrosis: One study links excess lactate accumulation from overtraining to signaling via lactylation and extracellular vesicles that induces hepatocyte apoptosis and liver fibrosis.

Note: These “downsides” are largely mechanistic/pathophysiologic findings in disease contexts, not typical side effects from lactate as a consumer supplement. The abstracts provided do not quantify adverse events from lactate administration in humans.

5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?

  • No direct pharmacogenomic conclusions can be made from these abstracts. The provided text does not report genotype-stratified outcomes or specific inherited variants that predict benefit/harm from lactate exposure or lactate-targeting therapies.

  • Gene/protein targets discussed (mechanistic relevance, not inherited-variant guidance):

    • HK2: Deletion (experimental) reduces histone lactylation-driven HSC activation and fibrosis in vivo; suggests HK2 pathway activity is important, but this is not presented as human genetic variation data.

    • LDHA: Highlighted as a potential therapeutic target in brain tumors; no clinical pharmacogenomic markers described.

    • MCT1 and HCAR1: Implicated in lactate uptake/signaling and ferroptosis resistance in HCC; again, no inherited-variant response data provided.

    • STAT5: In AML, drives glycolysis/lactate accumulation linked to PD-L1 via histone lactylation; not presented as a germline pharmacogenomic marker.

Practical takeaway: based on these abstracts alone, lactate-related pathways (LDH/MCT/HK2/HCAR1) are biologically important and may become therapeutic targets, but validated genetic variants guiding lactate-focused treatment decisions are not established here.

References

  1. The Warburg Effect: How Does it Benefit Cancer Cells?
    Maria V Liberti, Jason W Locasale (2016) - Trends in biochemical sciences
  2. Lactate and lactylation in cancer.
    Jie Chen, Ziyue Huang, Ya Chen, Hao Tian, Peiwei Chai, Yongning Shen, Yiran Yao, Shiqiong Xu, Shengfang Ge, Renbing Jia (2025) - Signal transduction and targeted therapy
  3. Lactate metabolism in human health and disease.
    Xiaolu Li, Yanyan Yang, Bei Zhang, Xiaotong Lin, Xiuxiu Fu, Yi An, Yulin Zou, Jian-Xun Wang, Zhibin Wang, Tao Yu (2022) - Signal transduction and targeted therapy
  4. Lactate: A key regulator of the immune response.
    Alba Llibre, Salih Kucuk, Atrayee Gope, Michelangelo Certo, Claudio Mauro (2025) - Immunity
  5. Lactate in the Regulation of Tumor Microenvironment and Therapeutic Approaches.
    Karen G de la Cruz-López, Leonardo Josué Castro-Muñoz, Diego O Reyes-Hernández, Alejandro García-Carrancá, Joaquín Manzo-Merino (2019) - Frontiers in oncology
  6. Hexokinase 2-mediated gene expression via histone lactylation is required for hepatic stellate cell activation and liver fibrosis.
    Hyunsoo Rho, Alexander R Terry, Constantinos Chronis, Nissim Hay (2023) - Cell metabolism
  7. Targeting the Warburg Effect in Cancer: Where Do We Stand?
    Ignasi Barba, Laura Carrillo-Bosch, Joan Seoane (2024) - International journal of molecular sciences
  8. Glycometabolic reprogramming-induced XRCC1 lactylation confers therapeutic resistance in ALDH1A3-overexpressing glioblastoma.
    Guanzhang Li, Di Wang, You Zhai, Changqing Pan, Jiazheng Zhang, Chen Wang, Ruoyu Huang, Mingchen Yu, Yiming Li, Xing Liu, Yanwei Liu, Fan Wu, Zheng Zhao, Huimin Hu, Zhongfang Shi, Ulf Dietrich Kahlert, Tao Jiang, Wei Zhang (2024) - Cell metabolism
  9. The Warburg effect: a signature of mitochondrial overload.
    Yahui Wang, Gary J Patti (2023) - Trends in cell biology
  10. HCAR1/MCT1 Regulates Tumor Ferroptosis through the Lactate-Mediated AMPK-SCD1 Activity and Its Therapeutic Implications.
    Youbo Zhao, Menghuan Li, Xuemei Yao, Yang Fei, Zhenghong Lin, Zhengguo Li, Kaiyong Cai, Yanli Zhao, Zhong Luo (2020) - Cell reports
  11. STAT5 promotes PD-L1 expression by facilitating histone lactylation to drive immunosuppression in acute myeloid leukemia.
    Ze-Wei Huang, Xue-Ning Zhang, Ling Zhang, Ling-Ling Liu, Jing-Wen Zhang, Yu-Xiang Sun, Jue-Qiong Xu, Quentin Liu, Zi-Jie Long (2023) - Signal transduction and targeted therapy
  12. The Regulation and Function of Lactate Dehydrogenase A: Therapeutic Potential in Brain Tumor.
    Cara J Valvona, Helen L Fillmore, Peter B Nunn, Geoffrey J Pilkington (2016) - Brain pathology (Zurich, Switzerland)
  13. Lactate Contribution to the Tumor Microenvironment: Mechanisms, Effects on Immune Cells and Therapeutic Relevance.
    Susana Romero-Garcia, María Maximina B Moreno-Altamirano, Heriberto Prado-Garcia, Francisco Javier Sánchez-García (2016) - Frontiers in immunology
  14. Muscle-derived small extracellular vesicles induce liver fibrosis during overtraining.
    Ya Liu, Rui Zhou, Yifan Guo, Biao Hu, Lingqi Xie, Yuze An, Jie Wen, Zheyu Liu, Min Zhou, Weihong Kuang, Yao Xiao, Min Wang, Genqing Xie, Haiyan Zhou, Renbin Lu, Hui Peng, Yan Huang (2025) - Cell metabolism
  15. Lactate and lactylation: Behind the development of tumors.
    Enci Dai, Wei Wang, Yingying Li, Defeng Ye, Yanli Li (2024) - Cancer letters
  16. Lactylation: novel epigenetic regulatory and therapeutic opportunities.
    Haoqin Fan, Fan Yang, Zhenghui Xiao, Haiyan Luo, Huaiyang Chen, Zhi Chen, Qiming Liu, Yunbin Xiao (2023) - American journal of physiology. Endocrinology and metabolism
  17. Astrocyte-derived lactate aggravates brain injury of ischemic stroke in mice by promoting the formation of protein lactylation
    Xiao-Yi Xiong, Xin-Ru Pan, Xia-Xia Luo, Yu-Fei Wang, Xin-Xiao Zhang (2024)
  18. L- and D-Lactate: unveiling their hidden functions in disease and health.
    Jianting Li, Peng Ma, Zhizhen Liu, Jun Xie (2025) - Cell communication and signaling : CCS
  19. Role of lactate and lactate metabolism in liver diseases (Review).
    Shun Yao, Hongyu Chai, Ting Tao, Li Zhang, Xingyue Yang, Xin Li, Zhiqiang Yi, Yongfeng Wang, Jiaxin An, Guorong Wen, Hai Jin, Biguang Tuo (2024) - International journal of molecular medicine
  20. Lactate metabolism and acute kidney injury.
    Hui Li, Qian Ren, Min Shi, Liang Ma, Ping Fu (2025) - Chinese medical journal


Want personalized supplement recommendations based on your genetics?
Upload Whole Genome Sequencing (WGS) raw DNA data today!
Or upload raw DNA data to get started with your free analysis!